8-K: McKesson Invests in Option Care Health Acquisition

McKesson Corporation and Clayton, Dubilier & Rice will acquire Option Care Health for approximately $5.8 billion, with McKesson taking a minority stake.

Summary

• McKesson Corporation, in partnership with Clayton, Dubilier & Rice (CD&R), has entered into a definitive agreement to acquire Option Care Health, Inc.
• The total enterprise value of the transaction is approximately $5.8 billion, with Option Care Health shareholders to receive $32.05 per share.
• CD&R will hold a majority ownership interest (approximately 51%), and McKesson will hold a minority interest (approximately 49%) for which it will invest $1.4 billion.
• Option Care Health will continue to operate as a separate company with its own management team.
• The transaction is expected to close in the first half of calendar year 2027, subject to customary closing conditions, including stockholder and regulatory approvals.
• Following the close, Option Care Health's common stock will be delisted from Nasdaq, and it will become a privately held company.
• McKesson intends to account for its minority interest using the equity method.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, indicating strategic investment and potential growth, though the minority stake and future acquisition framework introduce some complexity.

Positives

• Strategic investment by McKesson aligns with its long-term strategy to expand access and affordability to innovative therapies across the care continuum.
• The acquisition is expected to enhance McKesson's capabilities in specialty pharmaceuticals and support care delivery in lower-cost community settings.
• Option Care Health's home and ambulatory infusion capabilities are well-aligned with McKesson's focus on accessible and affordable high-quality care.
• The transaction offers immediate cash value to Option Care Health stockholders, representing a premium of approximately 37% to its closing share price on October 5, 2026.
• Option Care Health will continue to operate as usual, maintaining its commitment to patients, providers, employees, and partners.
• The partnership with CD&R, a firm with deep experience in healthcare services, is expected to support Option Care Health's growth.

Negatives

• McKesson is acquiring only a minority stake initially, with a framework for future acquisition of CD&R's interest, introducing a phased ownership structure.
• Option Care Health will withdraw its previously disclosed financial guidance for Q3 2026 due to the transaction announcement.
• The transaction is subject to customary closing conditions, including stockholder and regulatory approvals, which could lead to delays or failure to close.
• Option Care Health's common stock will be delisted from Nasdaq, ceasing to be publicly traded.

Risks

• Failure to obtain required stockholder or regulatory approvals, or failure to satisfy other closing conditions, could prevent the transaction from closing.
• The transaction may be delayed or not completed as anticipated.
• McKesson may not achieve the expected benefits of its investment.
• Option Care Health may not achieve its expected growth or other outcomes.
• McKesson may record impairment or other charges relating to its investment.
• The ownership structure may adversely affect the transaction, industry relationships, or the businesses involved.
• Restrictions on Option Care Health's business operations during the pendency of the transaction could impact its ability to pursue certain opportunities.
• Announcements related to the transaction could have adverse effects on Option Care Health's stock price, credit ratings, or operating results.

Future Outlook

McKesson views the investment as an important opportunity aligning with its long-term strategy to expand access and affordability to innovative therapies. Option Care Health is expected to continue investing strategically and accelerate technology deployment to improve clinical outcomes and reduce the total cost of care, supported by CD&R and McKesson's expertise.

Management Comments

• "We are pleased to have entered into this agreement, which provides immediate cash value for our stockholders. The Board of Directors completed an extensive assessment, involving thorough discussions with our advisors, and unanimously concluded this transaction maximizes value for our stockholders."
• "This transaction represents a great outcome for Option Care Health and our stockholders, and I want to thank our Board of Directors for their rigorous process and diligence. For more than 45 years, Option Care Health has helped transform the way infusion therapy is delivered, led by our team members unwavering commitment to providing extraordinary care to patients. We will continue to enhance our platform and deepen our partnerships with hospitals and health systems, physicians, payers, and biopharma manufacturers."
• "We are thrilled to have the support of CD&R and McKesson, empowering us to continue investing strategically and accelerate the pace of our advanced technology deployment to improve clinical outcomes and reduce the total cost of care. Both firms understand our business and the healthcare industry, and have proven track records of fostering growth for some of the largest and fastest-growing healthcare service businesses globally."
• "This investment represents an important opportunity that aligns with McKessons long-term strategy to expand access and affordability to innovative therapies across the care continuum. As these therapies continue to grow in importance and their delivery becomes increasingly complex, McKesson is focused on investing in areas where our capabilities can help improve access and advance care in lower-cost community settings, at or closer to home. Option Care Healths clinical model and national infusion footprint across home and ambulatory sites are well aligned with those priorities, and the company is well positioned for continued growth."
• "As a strategic investor, we look forward to bringing McKessons experience and expertise in specialty pharmaceuticals to support Option Care Healths strategy of broadening access to complex therapies and enabling care delivery in lower-cost settings, while creating long-term value for stakeholders."

Industry Context

StockSavvy.ai notes that this transaction reflects a broader trend in the healthcare services industry where private equity firms and large healthcare corporations are consolidating or investing in specialized providers like home and alternate site infusion services. This is driven by the increasing complexity and cost of specialty therapies, and a shift towards more patient-centric, lower-cost care settings.

Comparison to Industry Standards

• The acquisition premium of approximately 37% for Option Care Health is within the typical range for healthcare service companies undergoing strategic transactions, especially those with strong market positions in specialized areas like home infusion.
• McKesson's investment strategy aligns with other large distributors and healthcare service providers that are seeking to expand their reach into patient care services and specialty pharmacy management.
• CD&R's involvement highlights the continued interest of private equity in the healthcare sector, particularly in businesses that can benefit from operational improvements and strategic growth initiatives, similar to their past investments in companies like PharMerica.

Legal Proceedings

• Potential litigation relating to the proposed transaction is mentioned as a cost associated with the transaction.

Stakeholder Impact

• Shareholders of Option Care Health will receive $32.05 per share in cash, representing a significant premium.
• Employees of Option Care Health will continue to work under the existing management team, with an expectation of continued investment and growth.
• Patients will continue to receive care from Option Care Health with the same commitment.
• Providers, hospitals, health systems, physicians, payers, and biopharma manufacturers will continue to partner with Option Care Health, which is expected to enhance its platform and deepen partnerships.
• Creditors of Option Care Health may see a change in ownership structure, but the company is expected to remain a separate entity with continued operations.

Next Steps

• Option Care Health to release its third quarter 2026 financial results on November 4, 2026.
• Obtain approval from Option Care Health's stockholders.
• Receive required regulatory approvals.
• Complete the transaction, expected in the first half of calendar year 2027.
• Option Care Health's common stock will be delisted from Nasdaq upon closing.
• McKesson will account for its minority interest using the equity method.

Key Dates

Recommendation

McKesson's investment is strategic and aligns with its long-term goals, but the minority stake and the complexity of the deal structure warrant a 'hold' for investors focused on McKesson. For Option Care Health shareholders, the offer price is attractive, but the future outlook depends on the successful integration and continued growth under new ownership.

Keywords

infusion services, home infusion, alternate site infusion, specialty pharmaceuticals, healthcare services, acquisition, private equity, regulatory approvals